Abstract
Chemoimmunotherapy using nanotechnology has shown great potential for cancer therapy in the clinic. However, uncontrolled transportation and synergistic responses remain challenges. Here, a self-assembled selenopeptide nanoparticle that strengthens tumor chemoimmunotherapy through the activation of natural killer (NK) cells by the oxidative metabolite of the selenopeptide is developed. With the advantages of the enzyme-induced size-reduction and the reactive-oxygen-species-driven deselenization, this selenopeptide is able to deliver therapeutics, e.g., doxorubicin (DOX), to solid tumors and further activate the NK cells in a programmed manner. Importantly, in vitro and in vivo results prove the mutual promotion between the DOX-induced chemotherapy and the selenopeptide-induced immunotherapy, which synergistically contribute to the improved antitumor efficacy. It is anticipated that the selenopeptide may provide a type of promising stimuli-responsive immune modulator for versatile biomedical applications.
Original language | English (US) |
---|---|
Article number | 2108167 |
Pages (from-to) | e2108167 |
Journal | Advanced Materials |
Volume | 34 |
Issue number | 17 |
DOIs | |
State | Published - Apr 27 2022 |
Keywords
- chemoimmunotherapy
- drug delivery
- programmable nanomedicine
- selenopeptide
- self-assembly
- Killer Cells, Natural
- Humans
- Neoplasms/drug therapy
- Nanoparticles
- Immunotherapy
- Cell Line, Tumor
- Doxorubicin/pharmacology
- Nanomedicine
ASJC Scopus subject areas
- Mechanics of Materials
- Mechanical Engineering
- General Materials Science